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Abstract
Background: Quinine injection is the reference treatment for malaria when oral administration
is impossible. Quinine can also be administered by the intra-rectal route and, over the last ten
years, a series of studies have been conducted in children to determine the ideal dose and dilution
in the African situation. The aim of the present study was to evaluate the feasibility and usefulness
of a kit for an immediate administration of quinine alkaloids (Quinimax®) by community health
workers, prior to transfer of the child to a more sophisticated health care establishment.
Methods: A prospective, open, descriptive community intervention study conducted in northern
Senegal at six village Health Units in children fewer than ten years of age with non-per-os malaria.
Controls were given the routine care prior to transfer to a Health Center, and cases were in
addition administered Quinimax® (20 mg/ml) via the intra-rectal route before transfer. Patients
were followed through complete cure and parasitological tests were carried out on Days 0, 3 and 7.
Results: 134 patients (79 cases/55 controls) were recruited between November 2003 and May
2004 or October and November 2004. The two groups were comparable at inclusion. In the case
group, oral drugs could be administered after a mean of 16.8 hours versus 33.6 hours in the control
group. Time-to cure was shorter in cases than in controls. Complete parasite clearance was
obtained in all patients by Day 7. The kit was well accepted by all concerned and more than 80%
of community health workers judged the kit easy to use.
Conclusion: The emergency paediatric kit is a useful tool in the management of malaria in children
who cannot be treated orally. It is feasible and easy to use for health workers in community-based
Health Units where, according to the WHO, nearly 80% of malarial morbidity and mortality occurs.
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Background
Malaria is the most serious parasitic disease throughout
the tropics. According to the World Health Organization
(WHO), more than two billion people are exposed, most
of them living in Africa, the Americas and Southeast Asia.
Malaria accounts for about 25% of all children's deaths in
Africa [1]. Every year, more than 300 million people con-
tract acute malaria and, of these new clinical cases,
1.7–2.4 million die (mostly children). In Africa, nearly
80% of children undergoing a severe malaria attack die
before they reach any health care establishment, and only
a minority is given any specific treatment [2].
The recommended treatment for severe malaria includes
the injection, ideally intravenous, of quinine salts as soon
as the first signs of severe malaria or danger manifest
(WHO). However, community health structures possess
neither the equipment nor the expertise to perform this
type of procedure. The situation has to be improved so
that all children who develop severe malaria can be
treated as quickly as possible, beginning close to home.
Intra-rectal administration could provide a solution to
these problems. When oral administration is impossible,
community-based workers in remote village health care
units could administer treatment via this route, prior to
transferring the patient to a more sophisticated establish-
ment for comprehensive management.
A number of studies conducted in various countries in
Africa (Niger, Burkina Faso, Madagascar and Senegal)
have shown that intra-rectal administration of diluted
quinine is an effective, safe form of treatment in the man-
agement of malaria in children [3-6].
In Senegal, the health care system in more remote areas is
based on village-based health units run by community
health workers with no formal medical or paramedical
qualifications.
The aims of this study were (i) to study the feasibility of
an emergency pediatric kit when used by community
health workers; (ii)to evaluate the acceptance of this form
of treatment; (iii) to evaluate the therapeutic benefit of
immediate intra-rectal quinine administration in children




The village of Savoigne is located thirty kilometers north-
east of Saint Louis in the Senegal River Delta (Richard-Toll
district). The climate is Sahelian with a long dry season
between November and June, and a short rainy season
from July to October.
Malaria is unstable in this region with great variability
from one spot to another. The main vectors are Anopheles
pharoensis and Anopheles gambiae s.l. [7,8]. The Plasmo-
dium Index ranges from 5.20% to 38.50% in under-15
year-olds [9]. According to clinical data collected in the
Richard-Toll district in 2003, it is estimated that malaria
accounts for 35% of all local pathology.
Study design
A prospective, descriptive community intervention study
was conducted in children consulting community health
workers in six villages around the Savoigne Health Center
(Table 1). Most of the workers running the village-based
units have only primary school education, and they are
helped by local, unqualified midwives.
The six villages were randomized into two groups of three.
The first group named a control group in which the chil-
dren suffering from severe or non per os malaria were given
conventional treatment before referral to the Health
Center contains 3 villages. The second group of 3 villages
named case group (or intervention group) in which the
children received intra-rectal quinine before transfer.
These 2 groups were made in order to describe the refer-
ence towards the health center whether or not a adminis-
tration of quinine alkaloids was done to children with a
non per os or severe malaria attacks in a same area at the
same time. In order to investigate whether or not the sup-
plementary treatment delayed referral, the research team
did not get involved with the transfer of the sick children
to the Health Center.
Included were all children of under 25 kilograms and/or
10 years of age presenting with a suspected malarial attack
who could not be orally treated (severe or non per os
malaria). Children in whom intra-rectal quinine adminis-
tration was contra-indicated (because of diarrhoea or pre-
existing anal disease) were excluded from the case Group.
Parental consent was obtained before enrolment.
After treatment at the village-based unit, all parents were
told to take their sick children to the Health Center for
Table 1: Health Units around the Savoigne Health Center
Health Unit Distance from Health Center Population
Ndelle* 4 km 500 inhabitants
Barry 6 km 425 inhabitants
Ndiaye 7 km 1011 inhabitants
Ndioungue* 8 km 848 inhabitants
Mbodiène 9.5 km 912 inhabitants
Diagambal* 12.5 km 1086 inhabitants
* cases villages where intra rectal quinine was givenMalaria Journal 2007, 6:152 http://www.malariajournal.com/content/6/1/152
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confirmation of the diagnosis, curative treatment and fol-
low-up.
This Study was approved by the Senegalese Ethics & Scien-
tific Committee on October 22, 2003.
Procedures
In the control villages, the children were cared for in line
with national guidelines (paracetamol for high fever if
possible and referral). In the case villages, the included
children were also given an intra-rectal dose of 20 milli-
grams of quinine alkaloids per kilogram body weight
(diluted in water to 30 mg/ml). The paediatric kit con-
tains;
￿ one phial of 4 ml wich contains 500 mg of quinine alka-
loids composed by : 480 mg of quinine (770,25 mg of
quinine gluconate), 13,2 mg of quinidine (21,18 mg of
quinidine gluconate), 3,4 mg of cinchonine (4,24 mg of
cinchonine chlorhydrate) and 3,24 mg of cinchonidine
(4,03 mg of cinchonidine chlorhydrate). This quinine is
to be diluted into
￿ A bottle of 13,5 ml of purified water,
￿ a syringe graduated according to children bodyweight
and age wich to administrate by rectal route the reconsti-
tuted solution by rectal route
The child was then monitored for thirty minutes. During
this period, if any of the product was discharged, a further
half-dose was administered before referral.
On arrival at the Health Center, a blood smear was per-
formed to confirm the diagnosis and, for those with dem-
onstrated malaria, treatment was administered in
accordance with current National Malaria Control Pro-
gramme recommendations (IV quinine or referral to the
Regional Hospital). As soon as possible, the switch was
made to an oral regimen with the currently recommended
combination (SP + amodiaquine). At the Health Center,
the patient's clinical condition was monitored and parasi-
tological tests were performed every day until oral drugs
could be administered. The patients were followed up
through at least Day 7.
Statistical analysis
Two populations were analysed: Population 1 covering all
eligible patients included at the village units who were
referred to the Health Center; and Population 2 covering
all eligible patients included at the village units who were
found to have a confirmed parasitaemia on arrival at the
Health Center.
The statistical analysis was performed using SAS software
Version 8.2 (SAS Institute – Cary, NC). Descriptive analy-
ses were carried out for each treatment group. The statisti-
cal significance threshold was set at 5%. The analysis
describe the time-to referral and clinical outcome in the
intervention zone (case group with intra rectal quinine)
versus the control group or non intervention zone.
Results
A total of 134 children (79 in case villages and 55 in con-
trol villages) were included in two phases, the first
between November 2003 and May 2004, and then from
October to November 2004.
Description of the two groups at inclusion
At inclusion, demographic characteristics were the same
in the two groups (Table 2)
The time elapsed since appearance of the first symptoms
was the same (mean = 52 hours in both groups) and
symptoms were similar – exceptions were the incidences
of: hallucinations reported by 32.9% (n = 26) cases versus
45.5% (n = 25) controls; and agitation reported by 51.9%
(n = 41) cases and 70.9% (n = 39) controls (Table 3).
Feasibility and acceptance of the kit (79 Cases)
After pre-calibrated dilution of the Quinimax® solution,
the health worker withdrew the volume corresponding to








Male 43 (54.4%) 30 (54.5%) 73 (54.5%)
Female 36 (45.6%) 25 (45.5%) 61 (45.5%)
Ethnic origin
Peulh 9 (11.4%) 8 (14.5%) 17 (12.7%)
Woolof 69 (87.3%) 46 (83.6%) 115 (85.8%)
Serere 1 (1.3%) 0 1 (0.7%)
Diola 0 1 (1.8%) 1 (0.7%)
Age (years)
Mean (SD) 4.6 (2.6) 4.7 (2.7) 4.7 (2.6)
Median [Q1; Q3] 4.0 [2.5;6.0] 4.5 [2.7;6.0] 4.0 [2.5;6.0]
(Minimum; Maximum) 1;10 1;10 1;10
Weight (Kg)






Median [Q1; Q3] [10.20;17.00] [10.00;16.00] [10.00;16.00]
(Minimum; Maximum) 7.5;25.3 4.0;27.0 4.0;27.0
Temperature (°C)






Median [Q1; Q3] [38.40;39.40] [38.10;39.50] [38.40;39.50]
(Minimum; Maximum) 34.9;40.5 32.7;40.2 32.7;40.5Malaria Journal 2007, 6:152 http://www.malariajournal.com/content/6/1/152
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the child's weight (using a syringe with kilogram gradua-
tions).
The administered dose was considered correct if the dose
administered corresponded exactly to the child's weight: it
was found to be correct in 93.6% of cases (and the devia-
tions detected in the remaining cases were small)(Table
4).
Administering the product was deemed easy in 77.2% of
cases, and some of the difficulty of administration may be
related the patients' reactions which were observed in
39% (n = 31), including agitation, crying out and tears
(probably due to fear on introduction of the device). No
parental reactions were reported. In 25% of cases, early
discharge of the product within 30 minutes of the first
dose necessitated the administration of a further half-dose
of intra-rectal Quinimax®.
Time-to transfer from the Health Unit to the Health 
Center (n = 134 children)
All 134 patients were referred to the Savoigne Health
Center. The mean time-to transfer in this rural area was
4.40 hours (± 11.07) in the case group, and 3.11 hours (±
5.76) in the control group for the parents to bring chil-
dren from their villahe to the health post.
Therapeutic benefit
This end point was evaluated by comparing the cases and
the controls with a confirmed parasitaemia (n = 92) vis-à-
vis fever and parasitaemia over time, as well as the time
intervals to obtain cure, to stop vomiting and to the switch
to oral drugs.
Time-to cure
On Day 1, fewer cases than controls had fever (71.4% ver-
sus 93.0%). This difference persisted through Day 2 but
had disappeared by Day 3 (Figure 1).
Vomiting stopped within one day in 97.8% cases and
79.5% controls (Table 5).
The mean number of days between the day of the consul-
tation (and intra-rectal quinine administration at the vil-
lage Health Unit for the cases) and the switch to oral drugs
was significantly shorter in the case group than in the con-
trol group (0.7 days versus 1.4 days) (Table 6).
Percentage of patients with fever Figure 1

























































Yes 66 (83.5%) 39 (70.9%) 105 (78.4%)
Non 13 (16.5%) 16 (29.1%) 29 (21.6%)
Convulsions
Yes 3 (3.8%) 7 (12.7%) 10 (7.5%)
Non 76 (96.2%) 48 (87.3%) 124 (92.5%)
Loss of consciousness
Yes 2 (2.5%) 4 (7.3%) 6 (4.5%)
Non 77 (97.5%) 51 (92.7%) 128 (95.5%)
Agitation
Yes 41 (51.9%) 39 (70.9%) 80 (59.7%)
No 38 (48.1%) 16 (29.1%) 54 (40.3%)
Hallucinations
Yes 26 (32.9%) 25 (45.5%) 51 (38.1%)
No 53 (67.1%) 30 (54.5%) 83 (61.9%)
Bloody feces
Yes 4 (5.1%) 2 (3.6%) 6 (4.5%)
No 75 (94.9%) 53 (96.4%) 128 (95.5%)
Anal lesion
Yes 0 2 (3.6%) 2 (1.5%)
No 79 (100.0%) 53 (96.4%) 132 (98.5%)
Table 4: Dosing and ease of administration
Village cases
Correct dose Yes (93.6%)
No (6.4%)
Ease of administration Easy (77.2%)
Difficult (22.8%)
Quantity administered (kg eq.)
Mean (SD) 13.87 (4.43)
Median [Q1; Q3] 13.00 [10.00;17.00]
(Minimum; Maximum) 7.5;25.0Malaria Journal 2007, 6:152 http://www.malariajournal.com/content/6/1/152
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Similarly, the interval between consultation and cure was
shorter in the case group than in the control group (1.9
days versus 2.2 days;).
Parasite load
On Day 3, blood smear were carried out in the 92 patients
with parasitaemia on arrival at the Health Center. Parasite
clearance was recorded in 74.4% of cases and 69.2% of
controls (NS) (Figure 2).
Clearance was obtained in all patients by the end of the
follow-up period.
Safety of intrarectal Quinimax
Safety data (symptoms) collected at the Health Center
were analysed for all included patients.
On arrival at the Health Center, a difference was observed
between the two groups in the mean number of feces in
the preceding 24 hours: 1.2 in the case group versus 0.1 in
the control group (p < 0.0001).
Of the village children who passed a stool on arrival at the
Health Center (78 including six controls), eight cases
passed liquid stools compared with three controls (Table
7).
In the following days (Day 2 through Day 5), the number
of faeces per day in the two groups became comparable
(Table 8).
Serious Adverse Events
In the course of this Study, one control child died after
having been referred from the Health Center to Saint
Louis Regional Hospital (the referral center for severe
cases) with severe dehydration and clinical anaemia.
Discussion
This study was conducted to evaluate the feasibility and
safety of an emergency paediatric kit when used by
unqualified, community-based personnel, and to assess
acceptance of the kit by local people.
The community-based health workers were observed to
appreciate this novel therapeutic device.
Malaria was incorrectly diagnosed by community health
workers in 22% of cases in this Study. The mean percent-
age of mistaken diagnoses has been estimated at 45% in
certain health care structures in Senegal [10], and at 62%
at the Muraz Center (Bobo Dioulasso/Burkina Faso) in
Percentage of patients with parasitemia from Day 0 to Day 7 Figure 2
















Table 5: Time-to stoppage of vomiting
Number of days to the stoppage of vomiting
All included patients Cases Controls Total
N = 134
≤1 day 71 (95.9%) 38 (76.0%) 109 (87.9%)
> 1 day 3 (4.1%) 12 (24.0%) 15 (12.1%)






≤1 day 45 (97.8%) 31 (79.5%) 76 (89.4%)
> 1 day 1 (2.2%) 8 (20.5%) 9 (10.6%)
Unknown 3 4 7
Table 6: Time-to switch to oral drugs
Time-to switch (days) Cases Controls Total
N4 7 4 2 8 9
Mean (SD) 0.7 (0.8) 1.4 (0.7) 1.0 (0.8)
Median [Q1;Q3] 1.0 [0.0;1.0] 1.0 [1.0;2.0] 1.0 [1.0;1.0]
Minimum;Maximum 0;5 1;4 0;5Malaria Journal 2007, 6:152 http://www.malariajournal.com/content/6/1/152
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the context of severe malaria [11]. This suggests that regu-
lar training and close supervision can improve the accu-
racy of malaria diagnosis by community health workers.
The administration of treatment prior to referral did not
delay transfer of children to a more sophisticated health
care facility for parenteral management.
The emergency paediatric kit is an effective tool in the
early management of malaria in children who cannot be
treated orally. Its use significantly cut down the period of
time before the switch could be made to oral drugs, and
accelerated clinical cure.
The percentage of children in whom early discharge of the
administered product was observed was higher in this
study (25%) than those reported by Barennes (12.9%)[2]
and Ndiaye (12.1 %) [12]. Such discharge within thirty
minutes will cut down the concentration of quinine in the
blood but this can be compensated by administering
another half-dose [13]. No particular adverse reactions
were noted in patients who were given the second admin-
istration. Compression of the buttocks for five minutes
after administration reduces the risk of discharge.
No serious adverse reaction to the product was observed
in the course of this study, and none had been reported in
either Madagascar, where intrarectal quinine administra-
tion has been common since 1985 [14] or in clinical trials
in Niger, Togo, the Congo and Senegal [15,12]. In Niger,
where a policy based on intrarectal quinine administra-
tion was officially adopted in 1994, Harouna reported a
major anal abscess following this form of treatment in a
patient who had previously experienced severe complica-
tions following intramuscular quinine injection; the
abscess was cured with treatment [16].
Conclusion
The paediatric kit used in this study provides a useful ther-
apeutic option for early, community-based malaria man-
agement in children who cannot be treated orally, until
they can be transferred to a more sophisticated health care
establishment for definitive care. It is feasible at the com-
munity level and simple to use. Its generalization should
be accompanied by the training of community health
workers on how to use it, as well as its specific indications
and contraindications.
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